Erschienen in:
02.06.2016 | Original Scientific Report
Prognostic Analysis of Surgical Resection for Pulmonary Metastasis from Hepatocellular Carcinoma
verfasst von:
Yusuke Takahashi, Norihiko Ikeda, Jun Nakajima, Noriyoshi Sawabata, Masayuki Chida, Hirotoshi Horio, Sakae Okumura, Masafunmi Kawamura, The Metastatic Lung Tumor Study Group of Japan
Erschienen in:
World Journal of Surgery
|
Ausgabe 9/2016
Einloggen, um Zugang zu erhalten
Abstract
Introduction
Pulmonary metastases are the most common among extrahepatic recurrences from hepatocellular carcinoma (HCC). It causes high risk of HCC-related death, despite recent progress in therapeutic options. However, a role of pulmonary metastasectomy as well as prognostic factors after metastasectomy has not been well established. We aimed to investigate survival outcomes and prognostic factors after pulmonary resection for metastases from HCC.
Methods
A series of 93 patients who underwent pulmonary resections for metastases from HCC between June 1990 and July 2013 from multi-institutional database were retrospectively evaluated. Perioperative clinicopathological data and their association with prognosis were investigated.
Results
Of 93 patients, 77 had one pulmonary metastasis, and 16 had two or more. Recurrence after pulmonary resection was noted in 60 patients (64.5 %). The estimated 5-year overall survival rate was 41.4 % with median survival time after pulmonary metastatectomy of 39.0 months. Univariate prognostic analysis showed that disease-free interval of ≥12 months was significantly associated with favorable outcomes in both overall survival (5-year rate, 59.3 vs. 28.7 %, p = 0.026) and disease-specific survival (5-year rate, 62.5 vs. 36.2 %; p = 0.038) after pulmonary metastatectomy. A multivariate analysis revealed that disease-free interval was an independent prognostic factor (HR = 2.020, 95 % CI, 1.069–3.816, p = 0.030).
Conclusion
We have shown that a disease-free interval was an independent prognostic factor in patients who underwent pulmonary resection for metastasis from HCC. Also, pulmonary metastasectomy can be one of the therapeutic choices for select patients.